Speaker Profile

Ph.D., VP R&D, MedGenome

As the Head of R&D at MedGenome, my focus is to leverage next generation sequencing technologies to investigate diseases and develop solutions for efficient translation of therapies in the clinic. In the area cancer immunotherapy, I have developed a genomics-based integrated platform OncoPept, which combines four separate solutions: A high throughput cancer vaccine discovery and validation solution; tumor microenvironment analysis; TCR repertoire analysis; and the prediction of immune-related toxicity associated with checkpoint inhibitors. This platform is used by pharma and biotech companies in their preclinical and clinical studies. For over 15 years I have been working in the area of high throughput genomics and proteomics-based drug discovery research first in a mid-size genomics company CuraGen Corporation, followed by at Genentech, a large pharmaceutical company. I have done my graduate studies in Biochemistry followed by post-doctoral work in yeast genetics and B-cell biology.

Immunotherapy Showcase: MedGenome
MedGenome accelerates biomarker discovery leveraging population genetics and NGS-based solutions.

Overcoming Challenges in Personalized Cancer Vaccine Design
Cancer vaccine therapy is a promising tool to fight cancer. The goal of cancer vaccines is to produce strong anti-tumor response against tumor-specific neoantigens. The presentation will discuss challenges in designing effective cancer vaccines and strategies to overcome them.

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.